Chronic Mucocutaneous Candidiasis: Disease-Characteristics Report

Executive summary and scope

Chronic mucocutaneous candidiasis (CMC) is a clinical phenotype, not one molecularly uniform disease. It comprises persistent or recurrent, usually non-invasive Candida infection of oral, esophageal, genital, cutaneous, and nail surfaces. Candida albicans predominates. CMC may be relatively isolated—particularly with direct IL-17 pathway defects—or part of broader inborn errors of immunity such as STAT1 gain-of-function (GOF), CARD9 deficiency, or AIRE-associated autoimmune polyendocrine syndrome type 1 (APS-1/APECED). Thus, “Mendelian CMC” should be represented as a disease family with genotype-specific child entities rather than as a single-gene disorder. A recent review summarizes it as recurrent or persistent infection of “nails, skin, mouth, and genital organs,” and emphasizes defects in fungal recognition, IL-17 production/signaling, and Th17 development (published March 2024; DOI: https://doi.org/10.1097/INF.0000000000004321). (cinicola2024mucocutaneouscandidiasisinsights pages 1-2)

The strongest general causal model is: impaired epithelial IL-17 immunity → inadequate chemokine, antimicrobial-peptide, and neutrophil recruitment responses → failure to contain commensal Candida at barrier surfaces → recurrent/chronic candidiasis. STAT1 GOF is the most common currently recognized genetic cause and may account for up to approximately half of genetically investigated CMC, although ascertainment strongly affects that estimate. (egri2021primaryimmunodeficiencyand pages 1-2, egri2021primaryimmunodeficiencyand pages 7-8)

1. Disease information

Definition and identifiers

• Preferred name: Chronic mucocutaneous candidiasis; British spelling: chronic mucocutaneous candidosis.
• MONDO: MONDO:0015279.
• Orphanet: ORPHA:1334, Chronic mucocutaneous candidosis.
• MeSH concept: candidiasis/chronic mucocutaneous candidiasis is generally indexed under candidiasis and immunodeficiency-associated candidiasis; exact descriptor assignment should be verified against the current MeSH release.
• OMIM: there is no single OMIM entry adequately representing the whole phenotype. Molecular subtypes are distributed among familial candidiasis and gene-specific immunodeficiency entries; examples include direct IL-17-pathway deficiencies and STAT1-GOF-associated autosomal-dominant CMC.
• ICD: ICD-10-CM commonly places disease under candidiasis codes, selected by site—e.g., B37.0 oral, B37.2 skin/nail, B37.81 esophageal, B37.3 genital—and D84.89 or another immune-defect code when appropriate. ICD-11 similarly codes candidosis by site and the underlying inborn error separately. A unique universally used CMC code is not established.
• Synonyms: CMC; chronic mucocutaneous candidosis; chronic mucocutaneous Candida infection; familial chronic mucocutaneous candidiasis; candidiasis, familial; autosomal-dominant CMC when specifically STAT1/IL17F-related.

Open Targets independently maps MONDO:0015279 to IL17RA, STAT1, IL17RC, CLEC7A, TRAF3IP2, IL17F, and IL23R, while ORPHA:1334 additionally maps CARD9. This is aggregated disease-level evidence, not an individual-patient EHR dataset. (OpenTargets Search: chronic mucocutaneous candidiasis)

Data provenance

Most knowledge derives from aggregated rare-disease resources, pedigrees, case series, retrospective international cohorts, functional immune assays, and experimental models. Quantitative clinical frequencies below are primarily from genotype-selected STAT1-GOF cohorts and must not be generalized to every CMC genotype.

2. Etiology, risk, protective factors, and gene–environment interaction

CMC arises when normally commensal Candida encounters a heritable defect in epithelial antifungal immunity. Direct causes include abnormal fungal sensing (CLEC7A/Dectin-1–CARD9), reduced Th17 differentiation or cytokine production (STAT1 GOF, RORC), neutralization of IL-17-family cytokines in AIRE deficiency, or defective IL-17 ligand/receptor/adaptor function (IL17F, IL17RA, IL17RC, TRAF3IP2/ACT1). CARD9 deficiency differs because deep-organ and CNS candidiasis may occur. (egri2021primaryimmunodeficiencyand pages 5-6, cinicola2024mucocutaneouscandidiasisinsights pages 1-2, OpenTargets Search: chronic mucocutaneous candidiasis)

Table: This table summarizes the main genes and syndromic pathways linked to chronic mucocutaneous candidiasis in the gathered evidence. It distinguishes core IL-17/STAT1 causes from broader differentials such as APS-1, CARD9 deficiency, and syndromic Th17 disorders.

Genetic risk factors

• STAT1 GOF: heterozygous germline variants, usually autosomal dominant, with both familial and de novo disease. A 57-patient screen found variants in 35/57 (61%), including 26/39 familial (67%) and 9/18 sporadic cases (50%). Thirteen variants included p.M202V, p.A267V, p.R274W/Q, p.T385M/K, p.K388E, p.N397D, p.F404Y, p.F172L, p.Y287D, p.P293S, and p.S466R. (depner2016theextendedclinical pages 1-2)
• Direct IL-17 defects: IL17F is classically dominant-negative/autosomal dominant; IL17RA, IL17RC, and TRAF3IP2 deficiencies are generally biallelic/autosomal recessive loss-of-function disorders. Landmark human evidence is linked to PMID 21350122 for IL17F/IL17RA, PMID 25918342 for IL17RC, and PMID 24120361 for ACT1. (OpenTargets Search: chronic mucocutaneous candidiasis)
• CARD9, RORC, AIRE: generally biallelic recessive disease. AIRE causes APS-1 rather than isolated CMC; hypoparathyroidism and primary adrenal insufficiency are major diagnostic clues. (egri2021primaryimmunodeficiencyand pages 5-6, OpenTargets Search: chronic mucocutaneous candidiasis)
• Broader syndromic risk: STAT3 loss-of-function, DOCK8 deficiency and other combined immunodeficiencies can include CMC through reduced Th17 function but should not be labeled isolated familial CMC. (cinicola2024mucocutaneouscandidiasisinsights pages 9-9)

All established monogenic variants are germline. Somatic mosaicism, repeat expansions, mitochondrial variants, anticipation, and recurrent CMC-specific chromosomal rearrangements are not established major mechanisms. Pathogenic alleles are individually rare or absent from population databases; exact gnomAD frequency and ACMG classification must be retrieved per HGVS variant and transcript. A variant should not be classified from phenotype alone: segregation, population rarity, computational evidence, and—especially for STAT1—functional hyperphosphorylation/dephosphorylation assays are important.

Environmental and acquired risk factors

Antibiotic exposure, corticosteroid or other immunosuppression, HIV, diabetes, malnutrition, denture use, barrier trauma, and local moisture can promote ordinary mucocutaneous candidiasis and must be excluded as secondary explanations. In Mendelian CMC, these exposures may amplify disease but are not the primary cause. Persistent colonization and repeated azole exposure select resistant Candida, creating an important gene–environment–treatment interaction. Azole resistance is described as the principal limitation of long-term management. (egri2021primaryimmunodeficiencyand pages 1-2)

No reproducible genetic protective allele or specific protective diet/lifestyle intervention has been established. Practical protective factors are avoidance of unnecessary antibiotics/immunosuppression, good oral/dental and skin-fold hygiene, glycemic control, keeping affected skin dry, and culture-guided antifungal stewardship. These reduce exposure or complications but do not correct the inherited immune defect.

3. Phenotypes

Core phenotype and quantitative frequencies

A 26-person STAT1-GOF cohort found oral candidiasis in 73%, esophageal candidiasis in 65%, intertrigo in 50%, pustular skin disease in 46%, and scalp infection in 44%. Untreated oral disease became chronic in 42%, while 50% of affected patients had chronic cutaneous disease. Aphthous stomatitis occurred in 69%; 82% of those cases were recurrent. (depner2016theextendedclinical pages 6-8)

Suggested phenotype annotations include:

IDs should be validated against the target HPO release before database ingestion. Nail disease may impair walking, footwear use, manual work, and appearance; oral/esophageal disease impairs eating and causes pain; genital and visible skin disease affect intimacy and psychosocial wellbeing. No robust CMC-specific EQ-5D, SF-36, or PROMIS reference values were identified.

Extended STAT1-GOF phenotype

A 2024 synthesis reports more than 400 patients and over 100 STAT1-GOF variants. CMC occurs in over 60%; bacterial respiratory infection occurs in over 50% (lower respiratory disease approximately 37%), viral infections in roughly half, and autoimmunity in over 60%. More than 95% have onset before age 35, usually in early childhood. These frequencies describe STAT1 GOF, not direct IL-17 receptor deficiency. (meesilpavikkai2024unravelingtheimmunogenetics pages 4-7)

Complications include bronchiectasis from repeated respiratory infection, endocrinopathy, cytopenias, enteropathy, cerebral or large-vessel aneurysm/vasculopathy, and oral or esophageal squamous-cell carcinoma after longstanding inflammation. The literature review explicitly notes mouth/esophageal neoplasia and rare cerebral vasculitis. (egri2021primaryimmunodeficiencyand pages 1-2)

4. Genetic and molecular information

Functional consequences

STAT1 GOF variants cluster in coiled-coil, DNA-binding, SH2, and other functional domains. Many coiled-coil/DNA-binding variants impair nuclear dephosphorylation, prolonging phosphorylated STAT1; some SH2 variants increase phosphorylation by other means. This exaggerates IFN-driven transcription and interferes with STAT3-dependent Th17 differentiation. In four Iranian patients, p.R274Q and p.Q271P were associated with increased IFN-γ-induced STAT1 phosphorylation, reduced Th17 cells, reduced IL17A/IL17F/IL22 expression, and impaired Candida-specific T-cell proliferation. (ostadi2021functionalanalysisof pages 1-2, ostadi2021functionalanalysisof pages 7-8, meesilpavikkai2024unravelingtheimmunogenetics pages 4-7)

In one literature synthesis, 82% of STAT1-GOF patients had deficient CD4+IL-17+ cells. This is a useful supportive biomarker but not a perfectly sensitive diagnostic test. (ostadi2021functionalanalysisof pages 7-8)

Modifier, epigenetic, and structural evidence

Penetrance and expressivity are variable even within pedigrees, implying modifier genes, pathogen exposure, microbiome, treatment history, and stochastic immune effects. No validated CMC-specific modifier gene is ready for routine annotation. No reproducible disease-defining DNA-methylation, histone, chromatin, lipidomic, or metabolomic signature has been established. There is likewise no characteristic karyotypic abnormality, aneuploidy, translocation, or inversion.

5. Environmental and infectious information

The proximate infectious agent is usually Candida albicans—NCBI Taxonomy 5476—although other Candida species may occur. CMC is not ordinarily acquired by zoonotic transmission; it reflects failure to control endogenous or environmentally acquired commensal yeast at barrier sites. Fungal morphology and cell-wall β-glucans/mannans engage Dectin-1 and Toll-like receptors. CARD9 transduces C-type lectin signals and promotes cytokines needed for Th17 differentiation. (egri2021primaryimmunodeficiencyand pages 1-2, cinicola2024mucocutaneouscandidiasisinsights pages 1-2)

Smoking, alcohol, exercise, occupational toxins, radiation, or pollution are not established primary causes of Mendelian CMC. Tobacco and alcohol plausibly worsen oral/esophageal injury and cancer risk, but genotype-specific quantitative interaction data are lacking.

6. Mechanism and pathophysiology

Causal chain

1. Recognition: epithelial/myeloid CLEC7A/Dectin-1 and TLRs recognize Candida wall ligands.
2. Upstream signaling: CARD9-dependent innate signaling induces inflammatory cytokines; IL-6/IL-1/IL-23 and STAT3/RORγt support Th17 differentiation.
3. Effector production: Th17, γδ T cells, innate lymphoid cells, and other lymphocytes produce IL-17A/F and IL-22.
4. Barrier response: IL-17A/F engage IL-17RA/IL-17RC on keratinocytes and mucosal epithelial cells; ACT1/TRAF3IP2 activates NF-κB/MAPK programs, chemokines, antimicrobial peptides, and granulopoietic/neutrophil-recruiting signals.
5. Failure states: ligand/receptor/adaptor loss, low Th17 generation, anti-cytokine autoantibodies, or excessive STAT1 signaling interrupts this axis.
6. Clinical output: persistent epithelial colonization becomes symptomatic oral, esophageal, genital, cutaneous, and nail candidiasis. Chronic inflammation and repeated infection contribute downstream to scarring, structural lung disease, and malignancy.

The centrality of IL-17 is supported by human Mendelian defects across IL17F, IL17RA, IL17RC and TRAF3IP2 and by the common reduced Th17 phenotype in STAT1 GOF. (egri2021primaryimmunodeficiencyand pages 5-6, OpenTargets Search: chronic mucocutaneous candidiasis)

Suggested biological-process terms include GO:0045087 innate immune response, GO:0006955 immune response, GO:0032496 response to lipopolysaccharide only if experimentally appropriate, GO:0071346 cellular response to interferon-γ, GO:0032743 positive regulation of IL-17 production, GO:0030593 neutrophil chemotaxis, GO:0009617 response to bacterium/fungus-specific child term, and GO:0050832 defense response to fungus. Suggested cell types include CL:0000542 lymphocyte, CL:0000899 T-helper 17 cell, CL:0000624 CD4-positive alpha-beta T cell, CL:0000775 neutrophil, CL:0000451 dendritic cell, CL:0000576 monocyte, CL:0000312 keratinocyte, and mucosal epithelial-cell terms appropriate to site.

Recent molecular profiling

A 2023 three-adult study combined CyTOF and a 265-protein Olink panel during JAK inhibition. Clinical CMC improved, and one strong responder had greater Candida-specific reactivity after seven weeks. NK cells increased CD45/CD52/CD99; monocytes and eosinophils reduced CD16; CXCL10, annexin A1, granzymes B/H, and oncostatin M fell while FGF21 rose; IFN-γ and CXCL10 were reduced at three months. The abstract states: “Overall, JAK inhibitors improved clinical symptoms of CMC, but caused side effects in two patients.” (published 2023; DOI: https://doi.org/10.1007/s10875-022-01351-0). (borgstrom2023threeadultcases pages 1-2, borgstrom2023threeadultcases pages 7-11)

A separate 2023 ten-patient study showed immature, activated STAT1-GOF neutrophils with enhanced degranulation, NETosis, platelet aggregation, basal STAT1 phosphorylation, and interferon-stimulated genes. Ruxolitinib did not normalize this signature. The abstract states that neutrophils had a “strong propensity for degranulation, NETosis, and platelet-neutrophil aggregation.” (DOI: https://doi.org/10.1007/s10875-023-01528-1). (parackova2023neutrophilsinstat1 pages 1-3)

These are small exploratory studies. No validated single-cell atlas, spatial transcriptomic diagnostic signature, integrated lipidome/metabolome, or clinically deployed CRISPR-screen result was identified.

7. Anatomical structures affected

Primary sites are oral mucosa/tongue/oropharynx, esophageal epithelium, genital mucosa, epidermis and skin folds, scalp, periungual tissue, and nail plate/bed. Suggested UBERON annotations include oral epithelium, tongue, esophagus UBERON:0001043, skin of body UBERON:0002097, nail, scalp, vagina UBERON:0000996, and penis/glans where applicable. Disease is not lateralized.

Relevant tissues are stratified squamous epithelium and keratinized appendages. Key target/responding cells are keratinocytes and mucosal epithelial cells; immune participants include Th17 cells, neutrophils, monocytes, dendritic cells, NK cells, and B/T lymphocytes. Subcellular compartments depend on genotype: plasma membrane for IL-17RA/RC and Dectin-1; cytosol for CARD9 and ACT1; cytoplasm/nucleus for STAT1; nucleus for RORC and AIRE. Suggested GO cellular components include plasma membrane GO:0005886, cytoplasm GO:0005737, cytosol GO:0005829, and nucleus GO:0005634.

8. Temporal development

Onset is usually pediatric and insidious, often beginning as persistent oral thrush; most STAT1-GOF cases begin in early childhood, though diagnosis may be delayed into adulthood. More than 95% of STAT1-GOF patients reportedly manifest before 35 years. (egri2021primaryimmunodeficiencyand pages 7-8, meesilpavikkai2024unravelingtheimmunogenetics pages 4-7)

The natural course is chronic, episodic, and relapsing rather than a fixed staged disease. Oral disease can progress to nails, skin, esophagus, and genital sites. Treatment induces remission, but recurrence is common: in the 26-person STAT1 cohort, 87% of esophageal cases relapsed despite 67% achieving complete remission during treatment. (depner2016theextendedclinical pages 6-8)

Critical intervention periods include early childhood—before recurrent infection causes nutritional, dental, nail, or pulmonary injury—and before prolonged inflammation/azole exposure creates resistance or malignancy risk. Rapid recurrence after JAK-inhibitor withdrawal has been reported, so remission should not be equated with cure. (egri2021primaryimmunodeficiencyand pages 7-8)

9. Inheritance and population

Inheritance is genotype-specific: autosomal dominant for most STAT1 GOF and IL17F disease; autosomal recessive for IL17RA, IL17RC, TRAF3IP2, CARD9, RORC, and classic AIRE-associated APS-1. STAT1 GOF displays variable expressivity and may arise de novo. Penetrance is high but not uniformly quantified across variants. Anticipation is not expected. Germline mosaicism is theoretically possible but not a documented common mechanism.

CMC is ultra-rare, but reliable population-wide incidence or prevalence per 100,000 is unavailable because it is a phenotype spanning multiple disorders. APS-1 prevalence is approximately 1:100,000 globally, with enrichment in Finns, Sardinians, and Persian Jews. (egri2021primaryimmunodeficiencyand pages 5-6)

No consistent sex bias is established; one recent mechanistic cohort included 3 males and 7 females, but this is not an epidemiologic ratio. (parackova2023neutrophilsinstat1 pages 1-3) Founder effects and consanguinity are important for recessive AIRE, CARD9, and IL-17-pathway disease in particular populations. Carrier frequency must be calculated gene/variant/population-specifically from gnomAD; no defensible aggregate CMC carrier frequency exists.

10. Diagnostics

Clinical and microbiological evaluation

Diagnosis requires persistent/recurrent candidiasis confirmed by microscopy and culture or molecular identification, coupled with exclusion of common secondary causes. Record species and antifungal susceptibility, especially after azole exposure. Endoscopy with brushings/biopsy is appropriate for dysphagia or suspected esophageal disease. Histology typically shows yeast/pseudohyphae in superficial epithelium with inflammation; imaging is not routine unless evaluating lung damage, aneurysm/vasculopathy, deep fungal disease, or CARD9-associated CNS infection.

Immune work-up

Recommended baseline tests are CBC/differential, lymphocyte subsets (T, B, NK), immunoglobulins, HIV testing, glucose/HbA1c, liver/renal tests, and evaluation for endocrine autoimmunity. The review recommends quantifying T, B, and NK cells and ruling out secondary causes before establishing an inborn error. (egri2021primaryimmunodeficiencyand pages 5-6)

Genotype-directed functional tests include:

• frequency of circulating Th17/CD4+IL-17+ cells;
• Candida-specific T-cell proliferation/cytokine production;
• IL-17A, IL-17F, and IL-22 production;
• STAT1 phosphorylation after IFN-α, IFN-γ, or IL-27 and, where possible, dephosphorylation kinetics;
• anti-IL-17A/F and anti-IL-22 autoantibodies when APS-1 is suspected.

Flow-cytometric phospho-STAT1 testing is a rapid adjunct, not a substitute for molecular confirmation. In the international cohort, stimulated patient PBMCs showed hyperphosphorylation; the authors explicitly recommended it alongside genetic testing. (depner2016theextendedclinical pages 1-2, depner2016theextendedclinical pages 5-6)

Genetic testing strategy

1. Use an inborn-error-of-immunity/CMC panel including at minimum STAT1, IL17F, IL17RA, IL17RC, TRAF3IP2, CARD9, CLEC7A, RORC, AIRE, plus syndromic genes such as STAT3 and DOCK8.
2. If phenotype strongly suggests STAT1 GOF, sequence STAT1 with copy-number analysis and functional validation.
3. If panel-negative, proceed to trio WES or WGS; WGS is valuable for noncoding, copy-number, and structural variants.
4. Reanalyze periodically as disease genes expand.
5. CMA/karyotype/FISH, mtDNA, and repeat-expansion testing are not first-line unless unrelated features suggest another diagnosis.

Cascade testing is appropriate after a pathogenic familial variant is found. Prenatal and preimplantation testing are technically feasible for a known familial variant.

Differential diagnosis

Exclude HIV, diabetes, antibiotics/corticosteroids, neutropenia, severe combined/combined immunodeficiency, hyper-IgE syndrome, DOCK8 deficiency, common variable immunodeficiency, chronic granulomatous disease, APS-1, CARD9 deficiency, thymoma-associated immunodeficiency, and ordinary recurrent vulvovaginal candidiasis. Deep CNS candidiasis strongly suggests CARD9; candidiasis plus hypoparathyroidism/Addison disease suggests AIRE; CMC plus viral/bacterial infection, autoimmunity, and vasculopathy suggests STAT1 GOF.

11. Outcome and prognosis

There are no validated 5- or 10-year survival statistics for CMC as a whole. Isolated IL-17-pathway disease is often compatible with long survival but requires chronic antifungal management. Prognosis worsens with invasive fungal disease, recurrent bacterial/viral infection, bronchiectasis, endocrine crisis, vasculopathy/aneurysm, malignancy, or multidrug-resistant Candida.

In the 26-person STAT1 cohort, azoles produced partial remission in 62% and complete response in 38%; 58% required antifungal prophylaxis. (depner2016theextendedclinical pages 6-8) HSCT evidence is highly selected: one review summarized only 4/15 symptomatic patients achieving immune reconstitution while 9 died, indicating substantial transplant risk and likely confounding by severe baseline disease. Outcomes were better when transplantation occurred in stable patients. (egri2021primaryimmunodeficiencyand pages 8-9)

Longstanding mouth/esophageal inflammation warrants surveillance because squamous-cell carcinoma is reported. Functional morbidity includes pain, dysphagia, poor intake, nail destruction, recurrent medical care, treatment toxicity, and psychosocial burden. Validated prognostic biomarkers are lacking; candidate markers include genotype/domain, infection burden, organ damage, autoimmunity, treatment response, CXCL10/IFN signature, and persistent neutrophil activation.

12. Treatment and real-world implementation

Antifungal therapy

First-line treatment is usually a topical agent for limited disease and a systemic azole—commonly fluconazole—for extensive, nail, esophageal, or recurrent disease. Culture and susceptibility testing should guide refractory disease. Alternatives include itraconazole, posaconazole, voriconazole, isavuconazole, echinocandins, and amphotericin B according to site, species, resistance, interactions, and toxicity. Azoles inhibit fungal lanosterol 14α-demethylase; echinocandins inhibit β-1,3-D-glucan synthase; amphotericin binds ergosterol. Suggested NCIt intervention terms include Fluconazole, Itraconazole, Voriconazole, Posaconazole, Isavuconazole, Amphotericin B, Caspofungin/Micafungin/Anidulafungin, Antifungal Therapy, and Hematopoietic Stem Cell Transplantation.

Long-term suppression is frequently needed, but monitor hepatic toxicity, QT effects, drug interactions, and resistance. In the 26-person cohort, treatment often controlled rather than eradicated disease. (depner2016theextendedclinical pages 6-8)

Genotype-directed immune therapy

Ruxolitinib and baricitinib inhibit JAK signaling upstream of STAT1 and are off-label precision therapies for severe STAT1 GOF with refractory CMC or autoimmunity. They can improve IL-17 responses and clinical disease, but infection, cytopenia, liver injury, thrombosis and viral reactivation require monitoring. Treatment duration is undefined and relapse may follow withdrawal. (egri2021primaryimmunodeficiencyand pages 7-8)

In three adults, baricitinib 2 mg/day improved mucocutaneous inflammation within one month in one patient. Another stopped after three weeks because of painful aphthae, cough, fever, and elevated liver enzymes. Ruxolitinib 15 mg/day initially helped a third patient, but recurrent respiratory infections developed after one year; that patient subsequently improved after HSCT. (borgstrom2023threeadultcases pages 12-13, borgstrom2023threeadultcases pages 4-5)

HSCT is potentially curative but should be reserved for severe, life-threatening, medically refractory immune dysregulation after expert multidisciplinary assessment; published mortality is substantial. (egri2021primaryimmunodeficiencyand pages 7-8, egri2021primaryimmunodeficiencyand pages 8-9)

Experimental/registered studies

Relevant registered implementations include NIH natural-history study NCT01386437 (recruiting; planned enrollment 1,200), phase 2 oral MAT2203 in mucocutaneous candidiasis NCT02629419 (completed; n=4), phase 3 ibrexafungerp for refractory/intolerant fungal disease NCT03059992 (completed; n=233, not CMC-specific), and anti-cytokine-autoantibody disease study NCT01842386 (completed; n=7). These registrations establish research activity, not routine efficacy for Mendelian CMC.

No approved gene, RNA, or CRISPR therapy exists. No established CMC-specific pharmacogenomic dosing guideline from CPIC/PharmGKB was identified; CYP-mediated interactions remain clinically important for azoles.

13. Prevention

There is no licensed Candida vaccine or population screening program for CMC. Primary prevention of the germline disorder is limited to reproductive counseling. Secondary prevention consists of early recognition, culture confirmation, immune/genetic diagnosis, cascade testing, and prompt treatment before irreversible tissue damage. Tertiary prevention includes susceptibility-guided suppression, oral/dental care, skin-fold care, endocrine surveillance, pulmonary monitoring, avoidance of unnecessary antibiotics, and surveillance for oral/esophageal malignancy in longstanding disease.

Families with a molecular diagnosis should receive counseling on genotype-specific recurrence: approximately 50% per pregnancy for a heterozygous autosomal-dominant variant and 25% affected/50% carrier risk when both parents carry the same autosomal-recessive allele. These are Mendelian expectations and may be modified by de novo status, penetrance, or parental mosaicism.

14. Other species and natural disease

Mucocutaneous candidiasis occurs in animals, but no well-established naturally occurring veterinary disorder was identified that is directly orthologous to the full human STAT1-GOF/IL-17-deficient CMC phenotype. Candida is generally opportunistic across species. The disease is not considered zoonotic in the usual sense; human CMC reflects host susceptibility rather than sustained animal-to-human transmission.

Relevant taxa include human NCBI Taxon 9606, mouse 10090, zebrafish 7955, and Candida albicans 5476. Orthologues of STAT1, IL17RA, CARD9, RORC, and TRAF3IP2 are evolutionarily conserved, supporting comparative mechanistic studies. Breed-specific VBO annotations and an OMIA-equivalent natural Mendelian syndrome were not established from the retrieved evidence.

15. Model organisms

• Mouse: Il17ra-knockout mice are highly susceptible to C. albicans; one study reported rapid death after systemic challenge, demonstrating IL-17RA’s role in fungal immunity. However, systemic candidiasis is not identical to chronic human mucocutaneous disease. (OpenTargets Search: chronic mucocutaneous candidiasis)
• Genetic mouse models: Stat1-GOF knock-in, Aire-null, Card9-null, Il17ra/Il17rc-null, Act1-deficient, and Rorc-deficient systems can dissect cytokine production, receptor signaling, autoantibodies, neutrophil recruitment, and organ tropism. Their limitations include species-specific Candida commensalism and immune development.
• Zebrafish: larval/adult C. albicans infection permits live imaging and antifungal screening, but does not reproduce human nail/oral chronicity.
• Cellular systems: patient PBMCs, Candida-stimulated whole blood, phospho-flow assays, primary keratinocytes, epithelial cultures, and gene-edited cell lines are the most directly translational models. Patient-derived organoids/iPSCs are plausible but not yet standard CMC platforms.

Applications include variant functional classification, defining STAT1 dephosphorylation, testing IL-17 signaling, evaluating Candida-specific lymphocyte responses, and preclinical JAK-inhibitor or antifungal studies.

Evidence quality, current expert interpretation, and knowledge gaps

The highest-confidence conclusions are that CMC is genetically heterogeneous, barrier IL-17 immunity is central, STAT1 GOF is the leading recognized cause, and management requires both fungal control and diagnosis of the underlying immune defect. The 2021 review’s abstract states: “The key immune defect is a disruption of the action of cytokine IL-17, whose most common genetic etiology is STAT1 gene gain-of-function mutations.” (DOI: https://doi.org/10.15586/aei.v49i1.20). (egri2021primaryimmunodeficiencyand pages 1-2)

The major limitations are rarity, referral bias, mixing of molecular subtypes, retrospective cohorts, and small uncontrolled treatment series. Epidemiologic incidence, genotype-specific penetrance, quality-of-life scores, variant-level carrier frequencies, long-term JAK-inhibitor safety, transplant selection criteria, protective modifiers, epigenomics, spatial/single-cell atlases, and validated prognostic biomarkers remain insufficiently defined. Accordingly, cohort percentages should always retain the genotype and denominator, and JAK inhibition should be described as promising off-label precision therapy—not established universal CMC treatment.

References

1. (cinicola2024mucocutaneouscandidiasisinsights pages 1-2): Bianca Laura Cinicola, Andrea Uva, Marzia Duse, Anna Maria Zicari, and Danilo Buonsenso. Mucocutaneous candidiasis: insights into the diagnosis and treatment. The Pediatric Infectious Disease Journal, 43:694-703, Mar 2024. URL: https://doi.org/10.1097/inf.0000000000004321, doi:10.1097/inf.0000000000004321. This article has 6 citations.

2. (egri2021primaryimmunodeficiencyand pages 1-2): Natalia Egri, Ana Esteve-Solé, Àngela Deyà-Martínez, Iñaki Ortiz de Landazuri, Alexandru Vlagea, AP Garcia, Celia Cardozo, Carolina Garcia-Vidal, Clara San Bartolomé, Marta Español-Rego, L Yiyi, Xavier Bosch-Amate, J Ferrando, Jordi Yagüe, Manel Juan, and Laia Alsina. Primary immunodeficiency and chronic mucocutaneous candidiasis: pathophysiological, diagnostic, and therapeutic approaches. Allergologia et immunopathologia, 49 1:118-127, Jan 2021. URL: https://doi.org/10.15586/aei.v49i1.20, doi:10.15586/aei.v49i1.20. This article has 26 citations and is from a peer-reviewed journal.

3. (egri2021primaryimmunodeficiencyand pages 7-8): Natalia Egri, Ana Esteve-Solé, Àngela Deyà-Martínez, Iñaki Ortiz de Landazuri, Alexandru Vlagea, AP Garcia, Celia Cardozo, Carolina Garcia-Vidal, Clara San Bartolomé, Marta Español-Rego, L Yiyi, Xavier Bosch-Amate, J Ferrando, Jordi Yagüe, Manel Juan, and Laia Alsina. Primary immunodeficiency and chronic mucocutaneous candidiasis: pathophysiological, diagnostic, and therapeutic approaches. Allergologia et immunopathologia, 49 1:118-127, Jan 2021. URL: https://doi.org/10.15586/aei.v49i1.20, doi:10.15586/aei.v49i1.20. This article has 26 citations and is from a peer-reviewed journal.

4. (OpenTargets Search: chronic mucocutaneous candidiasis): Open Targets Query (chronic mucocutaneous candidiasis, 18 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

5. (egri2021primaryimmunodeficiencyand pages 5-6): Natalia Egri, Ana Esteve-Solé, Àngela Deyà-Martínez, Iñaki Ortiz de Landazuri, Alexandru Vlagea, AP Garcia, Celia Cardozo, Carolina Garcia-Vidal, Clara San Bartolomé, Marta Español-Rego, L Yiyi, Xavier Bosch-Amate, J Ferrando, Jordi Yagüe, Manel Juan, and Laia Alsina. Primary immunodeficiency and chronic mucocutaneous candidiasis: pathophysiological, diagnostic, and therapeutic approaches. Allergologia et immunopathologia, 49 1:118-127, Jan 2021. URL: https://doi.org/10.15586/aei.v49i1.20, doi:10.15586/aei.v49i1.20. This article has 26 citations and is from a peer-reviewed journal.

6. (parackova2023neutrophilsinstat1 pages 1-3): Zuzana Parackova, Petra Vrabcova, Irena Zentsova, Anna Sediva, and Marketa Bloomfield. Neutrophils in stat1 gain-of-function have a pro-inflammatory signature which is not rescued by jak inhibition. Journal of Clinical Immunology, 43:1640-1659, Jun 2023. URL: https://doi.org/10.1007/s10875-023-01528-1, doi:10.1007/s10875-023-01528-1. This article has 16 citations and is from a domain leading peer-reviewed journal.

7. (meesilpavikkai2024unravelingtheimmunogenetics pages 4-7): Kornvalee Meesilpavikkai, N. Hirankarn, Virgil A.S.H. Dalm, P. M. Hagen, Willem A. Dik, and Hanna IJspeert. Unraveling the immunogenetics of stat proteins: clinical perspectives on gain-of-function and loss-of-function variants. Asian Pacific journal of allergy and immunology, May 2024. URL: https://doi.org/10.12932/ap-270124-1776, doi:10.12932/ap-270124-1776. This article has 7 citations and is from a peer-reviewed journal.

8. (depner2016theextendedclinical pages 1-2): Mark Depner, Sebastian Fuchs, Jan Raabe, Natalie Frede, Cristina Glocker, Rainer Doffinger, Effrossyni Gkrania-Klotsas, Dinakantha Kumararatne, T. Prescott Atkinson, Harry W. Schroeder, Tim Niehues, Gregor Dückers, Asbjørg Stray-Pedersen, Ulrich Baumann, Reinhold Schmidt, Jose L. Franco, Julio Orrego, Moshe Ben-Shoshan, Christine McCusker, Cristina Miuki Abe Jacob, Magda Carneiro-Sampaio, Lisa A. Devlin, J. David M. Edgar, Paul Henderson, Richard K. Russell, Anne-Bine Skytte, Suranjith L. Seneviratne, Jennifer Wanders, Hans Stauss, Isabelle Meyts, Leen Moens, Milos Jesenak, Robin Kobbe, Stephan Borte, Michael Borte, Dowain A. Wright, David Hagin, Troy R. Torgerson, and Bodo Grimbacher. The extended clinical phenotype of 26 patients with chronic mucocutaneous candidiasis due to gain-of-function mutations in stat1. Journal of Clinical Immunology, 36:73-84, Nov 2016. URL: https://doi.org/10.1007/s10875-015-0214-9, doi:10.1007/s10875-015-0214-9. This article has 177 citations and is from a domain leading peer-reviewed journal.

9. (egri2021primaryimmunodeficiencyand pages 8-9): Natalia Egri, Ana Esteve-Solé, Àngela Deyà-Martínez, Iñaki Ortiz de Landazuri, Alexandru Vlagea, AP Garcia, Celia Cardozo, Carolina Garcia-Vidal, Clara San Bartolomé, Marta Español-Rego, L Yiyi, Xavier Bosch-Amate, J Ferrando, Jordi Yagüe, Manel Juan, and Laia Alsina. Primary immunodeficiency and chronic mucocutaneous candidiasis: pathophysiological, diagnostic, and therapeutic approaches. Allergologia et immunopathologia, 49 1:118-127, Jan 2021. URL: https://doi.org/10.15586/aei.v49i1.20, doi:10.15586/aei.v49i1.20. This article has 26 citations and is from a peer-reviewed journal.

10. (cinicola2024mucocutaneouscandidiasisinsights pages 9-9): Bianca Laura Cinicola, Andrea Uva, Marzia Duse, Anna Maria Zicari, and Danilo Buonsenso. Mucocutaneous candidiasis: insights into the diagnosis and treatment. The Pediatric Infectious Disease Journal, 43:694-703, Mar 2024. URL: https://doi.org/10.1097/inf.0000000000004321, doi:10.1097/inf.0000000000004321. This article has 6 citations.

11. (depner2016theextendedclinical pages 6-8): Mark Depner, Sebastian Fuchs, Jan Raabe, Natalie Frede, Cristina Glocker, Rainer Doffinger, Effrossyni Gkrania-Klotsas, Dinakantha Kumararatne, T. Prescott Atkinson, Harry W. Schroeder, Tim Niehues, Gregor Dückers, Asbjørg Stray-Pedersen, Ulrich Baumann, Reinhold Schmidt, Jose L. Franco, Julio Orrego, Moshe Ben-Shoshan, Christine McCusker, Cristina Miuki Abe Jacob, Magda Carneiro-Sampaio, Lisa A. Devlin, J. David M. Edgar, Paul Henderson, Richard K. Russell, Anne-Bine Skytte, Suranjith L. Seneviratne, Jennifer Wanders, Hans Stauss, Isabelle Meyts, Leen Moens, Milos Jesenak, Robin Kobbe, Stephan Borte, Michael Borte, Dowain A. Wright, David Hagin, Troy R. Torgerson, and Bodo Grimbacher. The extended clinical phenotype of 26 patients with chronic mucocutaneous candidiasis due to gain-of-function mutations in stat1. Journal of Clinical Immunology, 36:73-84, Nov 2016. URL: https://doi.org/10.1007/s10875-015-0214-9, doi:10.1007/s10875-015-0214-9. This article has 177 citations and is from a domain leading peer-reviewed journal.

12. (ostadi2021functionalanalysisof pages 1-2): Vajiheh Ostadi, Roya Sherkat, Melanie Migaud, Seyed-Mehran Modaressadeghi, Jean-Laurent Casanova, Anne Puel, Nioosha Nekooie-Marnany, and Mazdak Ganjalikhani-Hakemi. Functional analysis of two stat1 gain-of-function mutations in two iranian families with autosomal dominant chronic mucocutaneous candidiasis. Medical mycology, 59:180-188, Jun 2021. URL: https://doi.org/10.1093/mmy/myaa043, doi:10.1093/mmy/myaa043. This article has 14 citations and is from a peer-reviewed journal.

13. (ostadi2021functionalanalysisof pages 7-8): Vajiheh Ostadi, Roya Sherkat, Melanie Migaud, Seyed-Mehran Modaressadeghi, Jean-Laurent Casanova, Anne Puel, Nioosha Nekooie-Marnany, and Mazdak Ganjalikhani-Hakemi. Functional analysis of two stat1 gain-of-function mutations in two iranian families with autosomal dominant chronic mucocutaneous candidiasis. Medical mycology, 59:180-188, Jun 2021. URL: https://doi.org/10.1093/mmy/myaa043, doi:10.1093/mmy/myaa043. This article has 14 citations and is from a peer-reviewed journal.

14. (borgstrom2023threeadultcases pages 1-2): Emilie W. Borgström, Marie Edvinsson, Lucía P. Pérez, Anna C. Norlin, Sara L. Enoksson, Susanne Hansen, Anders Fasth, Vanda Friman, Olle Kämpe, Robert Månsson, Hernando Y. Estupiñán, Qing Wang, Tan Ziyang, Tadepally Lakshmikanth, Carl Inge E. Smith, Petter Brodin, and Peter Bergman. Three adult cases of stat1 gain-of-function with chronic mucocutaneous candidiasis treated with jak inhibitors. Journal of Clinical Immunology, 43:136-150, Sep 2023. URL: https://doi.org/10.1007/s10875-022-01351-0, doi:10.1007/s10875-022-01351-0. This article has 32 citations and is from a domain leading peer-reviewed journal.

15. (borgstrom2023threeadultcases pages 7-11): Emilie W. Borgström, Marie Edvinsson, Lucía P. Pérez, Anna C. Norlin, Sara L. Enoksson, Susanne Hansen, Anders Fasth, Vanda Friman, Olle Kämpe, Robert Månsson, Hernando Y. Estupiñán, Qing Wang, Tan Ziyang, Tadepally Lakshmikanth, Carl Inge E. Smith, Petter Brodin, and Peter Bergman. Three adult cases of stat1 gain-of-function with chronic mucocutaneous candidiasis treated with jak inhibitors. Journal of Clinical Immunology, 43:136-150, Sep 2023. URL: https://doi.org/10.1007/s10875-022-01351-0, doi:10.1007/s10875-022-01351-0. This article has 32 citations and is from a domain leading peer-reviewed journal.

16. (depner2016theextendedclinical pages 5-6): Mark Depner, Sebastian Fuchs, Jan Raabe, Natalie Frede, Cristina Glocker, Rainer Doffinger, Effrossyni Gkrania-Klotsas, Dinakantha Kumararatne, T. Prescott Atkinson, Harry W. Schroeder, Tim Niehues, Gregor Dückers, Asbjørg Stray-Pedersen, Ulrich Baumann, Reinhold Schmidt, Jose L. Franco, Julio Orrego, Moshe Ben-Shoshan, Christine McCusker, Cristina Miuki Abe Jacob, Magda Carneiro-Sampaio, Lisa A. Devlin, J. David M. Edgar, Paul Henderson, Richard K. Russell, Anne-Bine Skytte, Suranjith L. Seneviratne, Jennifer Wanders, Hans Stauss, Isabelle Meyts, Leen Moens, Milos Jesenak, Robin Kobbe, Stephan Borte, Michael Borte, Dowain A. Wright, David Hagin, Troy R. Torgerson, and Bodo Grimbacher. The extended clinical phenotype of 26 patients with chronic mucocutaneous candidiasis due to gain-of-function mutations in stat1. Journal of Clinical Immunology, 36:73-84, Nov 2016. URL: https://doi.org/10.1007/s10875-015-0214-9, doi:10.1007/s10875-015-0214-9. This article has 177 citations and is from a domain leading peer-reviewed journal.

17. (borgstrom2023threeadultcases pages 12-13): Emilie W. Borgström, Marie Edvinsson, Lucía P. Pérez, Anna C. Norlin, Sara L. Enoksson, Susanne Hansen, Anders Fasth, Vanda Friman, Olle Kämpe, Robert Månsson, Hernando Y. Estupiñán, Qing Wang, Tan Ziyang, Tadepally Lakshmikanth, Carl Inge E. Smith, Petter Brodin, and Peter Bergman. Three adult cases of stat1 gain-of-function with chronic mucocutaneous candidiasis treated with jak inhibitors. Journal of Clinical Immunology, 43:136-150, Sep 2023. URL: https://doi.org/10.1007/s10875-022-01351-0, doi:10.1007/s10875-022-01351-0. This article has 32 citations and is from a domain leading peer-reviewed journal.

18. (borgstrom2023threeadultcases pages 4-5): Emilie W. Borgström, Marie Edvinsson, Lucía P. Pérez, Anna C. Norlin, Sara L. Enoksson, Susanne Hansen, Anders Fasth, Vanda Friman, Olle Kämpe, Robert Månsson, Hernando Y. Estupiñán, Qing Wang, Tan Ziyang, Tadepally Lakshmikanth, Carl Inge E. Smith, Petter Brodin, and Peter Bergman. Three adult cases of stat1 gain-of-function with chronic mucocutaneous candidiasis treated with jak inhibitors. Journal of Clinical Immunology, 43:136-150, Sep 2023. URL: https://doi.org/10.1007/s10875-022-01351-0, doi:10.1007/s10875-022-01351-0. This article has 32 citations and is from a domain leading peer-reviewed journal.

Artifacts

• Edison artifact artifact-00